|
|
|
|
LEADER |
03003nam a22002895i 4500 |
001 |
000280443 |
005 |
20200930133853.0 |
007 |
cr nn 008mamaa |
008 |
171024s2018 xxu| s |||| 0|eng d |
020 |
|
|
|a 9781493973743
|
024 |
7 |
|
|a 10.1007/978-1-4939-7374-3
|2 doi
|
040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
245 |
1 |
0 |
|a Duchenne Muscular Dystrophy :
|b Methods and Protocols /
|c edited by Camilla Bernardini.
|
250 |
|
|
|a 1st ed. 2018.
|
260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Humana,
|c 2018.
|
300 |
|
|
|a XII, 287 p. 49 illus., 34 illus. in color. :
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Methods in Molecular Biology,
|v 1687
|
505 |
0 |
|
|a An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.- Clinical Manifestations and Overall Management Strategies for Duchenne Muscular Dystrophy -- Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies -- Characterization of the Inflammatory Response in Dystrophic Muscle Using Flow Cytometry -- Imaging Analysis of the Neuromuscular Junction in Dystrophic Muscle -- System Biology Approach: Gene Network Analysis for Muscular Dystrophy -- Proteomic Profiling of the Dystrophin-Deficient Brain -- Probing the Pathogenesis of Duchenne Muscular Dystrophy Using Mouse Models -- Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy -- Designing Effective Antisense Oligonucleotides for Exon Skipping -- Identification of Splicing Factors Involved in DMD Exon Skipping Events Using an In Vitro RNA Binding Assay -- The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy -- PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment -- Proton Nuclear Magnetic Resonance (1H NMR) Spectroscopy-Based Analysis of Lipid Components in Serum / Plasma of Patients with Duchenne Muscular Dystrophy (DMD) -- Test of Anti-Fibrotic Drugs in a Cellular Model of Fibrosis Based on Muscle-Derived Fibroblasts from Duchenne Muscular Dystrophy Patients -- Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy -- Advanced Methods to Study the Cross-Talk Between Fibro-Adipogenic Progenitors and Muscle Stem Cells -- AAV6 Vector Production and Purification for Muscle Gene Therapy -- From gRNA Identification to the Restoration of Dystrophin Expression: A Dystrophin Gene Correction Strategy for Duchenne Muscular Dystrophy Mutations Using the CRISPR-Induced Deletion Method.
|
650 |
|
0 |
|a Molecular biology.
|
650 |
1 |
4 |
|a Molecular Medicine.
|
700 |
1 |
|
|a Bernardini, Camilla.
|e editor.
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|
900 |
|
|
|a Libro descargado a ALEPH en bloque (proveniente de proveedor)
|